URGN

NEUTRALProduct

UroGen Pharma Ltd.

2026-07-27

Price

$41.46

+1.20%

This is the 2026-07-27 snapshot — the signals and analysis for URGN as of this single trading day.

View full URGN research hub →

Score1.0Noise

Signals2/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

UroGen Pharma (URGN) is exhibiting High-Conviction Price Discovery, driven by recent structural pipeline advancements and a highly favorable macro environment. The stock's PERFECT_STACK and GOLDEN_CROSS signals are fundamentally validated by the recent FDA IND clearance for its UGN-501 oncolytic virus and a new U.S. patent allowance protecting ZUSDURI into 2044. With the broader market in a RISK_ON regime that aggressively favors high-beta assets, URGN's +18.4% relative strength versus the SPY confirms strong institutional appetite and momentum leadership rather than mere tape-drifting.

Fired Signals

GOLDEN CROSSPERFECT STACK

Key Takeaways

Actionable Thesis: URGN presents a strong momentum long setup, backed by PERFECT_STACK and GOLDEN_CROSS signals, as institutional buyers absorb shares following major FDA and patent catalysts.
Key Risk: Given the stock's elevated 45.6% annualized volatility, a failure to breach overhead 52-week high resistance could trigger a sharp mean-reversion pullback.
What to Watch: Monitor price action at the $43.93 52-week high for breakout confirmation, while keeping an eye on the $36.07 support level for risk management.

← Back to 2026-07-27 View Full URGN History →Yahoo Finance &nearr;